Biotech Values

[isolution]

Lucentis data ARVO 2004?

Dew, many thanks for your comments (always accurate). Few months ago (may 2003), I found an interesting report about ARVO at:

http://www.trends-in-medicine.com/May2003/ARVO053p.pdf

You can read at the bottom of left column/page 4 this comment about Genentech trials:

"Phase III trial in occult AMD. This trial is testing 300 mg
and 500 mg dose, given every 28 days. An official
indicated that, like anecortave, Lucentis enrollment may
take longer than previously expected.

Arvo abstracts will be online on february 23 and I feel like you, Genentech might not be able to show interim data at Arvo2004, but I bet they do all that is possible to make it.